# Intranasal Dexmedetomidine and Perioperative Myocardial Injury

Study · id `cardio:ct-nct07549282` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07549282](<https://clinicaltrials.gov/study/NCT07549282>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07549282

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT07549282. Randomized; quadruple masking; primary purpose prevention. Start 2026-08 (anticipated); primary completion 2027-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT07549282, source copy `cardio:ctgov-nct07549282-2026-07-30`, retrieved 2026-10-26)
- Planned start: 2026-08 (anticipated) (ClinicalTrials.gov record NCT07549282, source copy `cardio:ctgov-nct07549282-2026-07-30`, retrieved 2026-10-26)
- Primary completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07549282, source copy `cardio:ctgov-nct07549282-2026-07-30`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT07549282, source copy `cardio:ctgov-nct07549282-2026-07-30`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07549282, source copy `cardio:ctgov-nct07549282-2026-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07549282-2026-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intranasal Dexmedetomidine and Perioperative Myocardial Injury
- Condition: Coronary Heart Disease
- Condition: Myocardial Injury
- Condition: Myocardial Infarction
- Condition: Dexmedetomidine
- Intervention (Drug): Intranasal Dexmedetomidine
- Intervention (Drug): Normal saline
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: bf62ade2ff2b98b98bb6f69ce8df48ce3760cf256fd8d259f15abc7f52e271a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
